NovAccess Global IncOTCQB:XSNX
- LAST PRICE0.0051
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots500.4400/ 1
- Open / Previous Close0.0000 / 0.0051
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XSNX |
|---|---|---|
| 09:32 ET | 125000 | 0.0061 |
| 09:43 ET | 10000 | 0.0064 |
| 10:42 ET | 60000 | 0.0063 |
| 12:18 ET | 100000 | 0.0065 |
| 01:06 ET | 15000 | 0.00628 |
| 01:30 ET | 298100 | 0.0056 |
| 01:55 ET | 10000 | 0.006 |
| 01:57 ET | 58500 | 0.00604 |
| 02:00 ET | 90000 | 0.0056 |
| 02:02 ET | 50000 | 0.0055 |
| 02:04 ET | 181500 | 0.0052 |
| 02:08 ET | 10000 | 0.0051 |
| 02:09 ET | 578500 | 0.005 |
| 03:27 ET | 250000 | 0.0055 |
| 03:32 ET | 150000 | 0.0055 |
| 03:34 ET | 100000 | 0.0055 |
| 03:56 ET | 209954 | 0.0051 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NovAccess Global Inc | 141.1K | -0.1x | --- |
ContraFect Corp | 192.7K | 0.0x | --- |
Immunotech Laboratories Inc | 57.5K | 0.0x | --- |
Sienna Biopharmaceuticals Inc | 30.0 | 0.0x | --- |
PZ Wind Down Inc | 2.3K | 0.0x | --- |
ARYx Therapeutics Inc | 30.0 | 0.0x | --- |
Company Information
NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.
Contact Information
- Headquarters
- 8584 E. WASHINGTON STREET, NO. 127CHAGRIN FALLS, OH, United States 44023
- Phone
- 213-642-9268
- Fax
- 949-266-5823
Executives
- Independent Chairman of the Board
- John Cassarini
- Chief Executive Officer, Director
- Dwain Moris - Irvin
- Fractional Chief Financial Officer
- Neil Laird
- Independent Director
- Jason Anderson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $141.1K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 27.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.58 |
EPS | $-0.09 |
Book Value | $-0.36 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
